Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

24 Oct 2018

Abstract excerpt

Key Points There is no correlation between ctDNA and bone marrow for MRD by NGS using only immunoglobulin gene rearrangements in myeloma patients.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lymphoma Diagnosis and Treatment
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30355580
DOI: 10.1182/bloodadvances.2018025197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrowPMID 30355580Read ↗

Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma PatientsSemantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor DiseasesSemantic proximity Read ↗

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read ↗

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaSemantic proximity Read ↗

Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple MyelomaSemantic proximity Read ↗

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cellsSemantic proximity Read ↗

Monitoring minimal residual disease in the bone marrow using next generation sequencing.Semantic proximity Read ↗

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.Semantic proximity Read ↗

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.Semantic proximity Read ↗

Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma PatientsSemantic proximity Read ↗

Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.Semantic proximity Read ↗

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.